Participants 503 638 7
Adult patients with measurable, locally advanced, and/or metastatic RCC were randomly assigned 2:1 to receive oral pazopanib or placebo
Participants 899 994 9
Of 435 patients enrolled, 233 were treatment naive (54%) and 202 were cytokine pretreated (46%)
